NEWS RELEASE

NYSE American to Suspend Trading Immediately in ImmunoCellular Therapeutics, Ltd. (IMUC) and Commence Delisting Proceedings

10/16/2018

NEW YORK, October 16, 2018 – NYSE American LLC ("NYSE American" or the "Exchange") announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of ImmunoCellular Therapeutics, Ltd. (the "Company") — ticker symbol IMUC — and Warrants to purchase Common Stock $0.0001 par value per share (Expiring August 12, 2021) — ticker symbol IMUC WS — from the Exchange. Trading in the Company's securities on NYSE American will be suspended immediately.

NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003 of the NYSE American Company Guide, due to the abnormally low trading price of its common stock.

The Company has a right to a review of staff's determination to delist the common stock and the warrants by a committee of the Board of Directors of the Exchange. The NYSE American will apply to the Securities and Exchange Commission to delist the Company's common stock and the warrants upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff's decision.

Company Contact for ImmunoCellar Therapeutics, Ltd.:

Jane Green

(267) 457-3734 direct
(415) 652-4819 mobile
jane@jmgcomm.com